Adegramotide

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Adegramotide (DSP-7888) is an experimental drug intended for treatment of various hematologic malignancies and solid tumors, including glioblastoma multiforme. It is a peptide vaccine and has finished phase I clinical trials and phase II clinical trials. As of , phase III clinical research has been cancelled due to low efficacy markers during interim review of study data for Ombipepimut-S Emulsion (DSP-7888) in combination with Bevacizumab. The phase III trials for DSP-7888 with checkpoint inhibitors for platinum-resistant ovarian cancer, as of , is still continuing as planned.

Adegramotide (DSP-7888) is an experimental drug intended for treatment of various hematologic malignancies and solid tumors, including glioblastoma multiforme. It is a peptide vaccine and has finished phase I clinical trials and phase II clinical trials. As of , phase III clinical research has been cancelled due to low efficacy markers during interim review of study data for Ombipepimut-S Emulsion (DSP-7888) in combination with Bevacizumab. The phase III trials for DSP-7888 with checkpoint inhibitors for platinum-resistant ovarian cancer, as of , is still continuing as planned.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1330649820 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

5 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.